Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LXRX

Lexicon Pharmaceuticals Inc

Jun 17 • 12:54PM ET

0.7117

Dollar change +0.0417
Percentage change 6.22	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN BMRN INCY ALNY IONS NBIX KNSA ALLO

| Held by: VTI IWM VXF SCHA IWN VTWO VHT IWO IWC PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.51	Insider Own	51.26%	Shs Outstand	363.18M	Perf Week	1.51%
Market Cap	258.47M	Forward P/E	-	EPS next Y	-0.31	Insider Trans	0.00%	Shs Float	177.00M	Perf Month	32.98%
Income	-177.30M	PEG	-	EPS next Q	-0.07	Inst Own	26.54%	Short Float	21.94%	Perf Quarter	97.97%
Sales	31.21M	P/S	8.28	EPS this Y	49.60%	Inst Trans	-23.94%	Short Ratio	2.92	Perf Half Y	-13.44%
Book/sh	0.34	P/B	2.10	EPS next Y	2.36%	ROA	-49.60%	Short Interest	38.83M	Perf Year	-62.74%
Cash/sh	0.54	P/C	1.33	EPS next 5Y	30.30%	ROE	-86.09%	52W Range	0.28 - 2.45	Perf YTD	-3.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROIC	-95.22%	52W High	-70.95%	Beta	1.01
Dividend TTM	-	Quick Ratio	2.22	Sales past 5Y	-37.35%	Gross Margin	96.22%	52W Low	150.95%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	2.22	EPS Y/Y TTM	37.24%	Oper. Margin	-540.04%	RSI (14)	56.85	Volatility	1.67% 4.46%
Employees	103	Debt/Eq	0.86	Sales Y/Y TTM	1250.63%	Profit Margin	-568.04%	Recom	2.00	Target Price	2.92
Option/Short	Yes / Yes	LT Debt/Eq	0.51	EPS Q/Q	64.55%	Payout	-	Rel Volume	0.21	Prev Close	0.67
Sales Surprise	-10.65%	EPS Surprise	26.32%	Sales Q/Q	11.68%	Earnings	May 13 AMC	Avg Volume	13.31M	Price	0.71
SMA20	5.63%	SMA50	12.11%	SMA200	-23.10%	Trades		Volume	1,553,861	Change	6.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2 → $1
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26

Show Previous Ratings

Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks) -5.91%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +6.93%
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks) +8.46%
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
12:17PM	Loading…
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -5.03%
08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks) -5.66%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
08:00AM	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
11:09AM	Loading…
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%
May-19-25 08:00AM	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology (GlobeNewswire)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
May-14-25 09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance) -15.57%
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
03:18AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.51%
04:06PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
08:50AM	Loading…
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 04:30PM	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -8.90%
08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +8.40%
08:00AM	Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 06:10PM	Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) (Seeking Alpha) +64.13% -19.23%
04:17PM	Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1 (Investor's Business Daily)
01:04PM	Novo Nordisk strikes $1bn deal for Lexicons oral obesity drug (Pharmaceutical Technology)
07:30AM	Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 (GlobeNewswire)
Mar-07-25 08:30AM	Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) +6.55%
02:17AM	Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.43%
04:18PM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-25 04:15PM	Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire) +11.00%
Mar-03-25 07:00AM	Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire) -58.17%
Mar-02-25 04:13PM	Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire)
Feb-18-25 08:00AM	Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) (GlobeNewswire)
Jan-21-25 08:00AM	Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +14.25%
Jan-06-25 09:16AM	Heres Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +15.94%
Jan-02-25 08:00AM	Lexicon Appoints Scott Coiante as Chief Financial Officer (GlobeNewswire) +5.23%
Dec-20-24 04:30PM	Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) (GlobeNewswire) +15.71%
Nov-27-24 07:30AM	Lexicon completes subject enrolment for DPNP trial of LX9211 (Clinical Trials Arena)
Nov-26-24 08:00AM	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-25-24 04:15PM	Lexicon Pharmaceuticals to Participate in December Investor Conferences (GlobeNewswire) -5.81%
Nov-22-24 07:32AM	Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA (GlobeNewswire) +11.88%
05:05AM	Lexicon to disband sales team, lay off 60% of staff (BioPharma Dive)
Nov-20-24 04:05PM	Lexicon Appoints Ivan H. Cheung to Board of Directors (GlobeNewswire) -8.34%
Nov-14-24 08:00AM	Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago (GlobeNewswire)
Nov-13-24 02:20AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com) -8.40%
Nov-12-24 05:25PM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.30%
04:25PM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:15AM	Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-07-24 05:02PM	S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate (Investopedia) +7.44%
Nov-06-24 08:00AM	Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference (GlobeNewswire)
02:58AM	A diabetes drug, twice rejected, stumbles again but its developer persists (Pharma Voice)
Nov-05-24 04:05PM	Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
08:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 (GlobeNewswire)
Nov-04-24 08:00AM	Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss (GlobeNewswire)
Oct-31-24 06:54PM	Lexicon Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire)
Oct-27-24 05:35PM	FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting (TipRanks)
Oct-23-24 09:00AM	New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024 (GlobeNewswire)
Oct-22-24 08:00AM	Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Oct-17-24 07:15AM	Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe (BioPharma Dive) +5.24%
05:55AM	Lexicon partners Viatris for global expansion of sotagliflozin (Pharmaceutical Technology)
Oct-16-24 04:35PM	Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe (GlobeNewswire) +6.70%
04:34PM	Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe (PR Newswire)
Oct-09-24 03:53PM	Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ... (GuruFocus.com)
Sep-27-24 08:00AM	Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress (GlobeNewswire)
Sep-16-24 08:00AM	Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer (GlobeNewswire)
Sep-10-24 08:00AM	New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes (GlobeNewswire)
Sep-03-24 04:00PM	Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.94%
08:00AM	New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration (GlobeNewswire)
Sep-01-24 10:26PM	Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-22-24 11:26AM	Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista (Zacks)
10:33AM	Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD (Pharmaceutical Technology)
Aug-21-24 08:00AM	Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista (GlobeNewswire) +13.69%
Aug-14-24 12:33PM	Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up (Zacks) -5.20%
Aug-13-24 08:30AM	Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio (GlobeNewswire) +8.81%
07:00AM	Lilly opens R&D hub; Ovid and Lexicon lay off staff (BioPharma Dive)
Aug-07-24 08:00AM	Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists (GlobeNewswire)
Aug-01-24 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.22% -16.09%
04:12PM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 (GlobeNewswire) +7.37%
Jul-17-24 11:15AM	FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug (Zacks)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swain Judith L	Director	May 13 '25	Option Exercise	0.00	36,810	0	85,174	May 13 05:52 PM
Sullivan Diane E.	Director	May 13 '25	Option Exercise	0.00	36,810	0	36,810	May 13 05:51 PM
SOBECKI CHRISTOPHER J	Director	May 13 '25	Option Exercise	0.00	36,810	0	203,865	May 13 05:50 PM
BARKER SAM L	Director	May 13 '25	Option Exercise	0.00	36,810	0	124,459	May 13 05:50 PM
Amouyal Philippe	Director	May 13 '25	Option Exercise	0.00	36,810	0	285,174	May 13 05:49 PM
DEBBANE RAYMOND	Director	May 13 '25	Option Exercise	0.00	36,810	0	1,385,689	May 13 05:48 PM
COATS LONNEL	Former Affiliate	Aug 15 '24	Proposed Sale	1.60	300,000	480,000		Aug 15 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXRX

Lexicon Pharmaceuticals Inc

Upgrade your FINVIZ experience